allergic reaction. If the allergic reaction does occur, the patient should be treated with a Histamine blocker such as Benadryl, a steroid such as solu Medrol or dexamethasone to reduce inflammation and Epinephrine Subcutaneous of Intramuscular depending on the severity. Also in certain situations patients may require Albuterol/ipratromium bromide nebulized treatments for shortness of breath caused by bronchospasms and IV fluids such as normal saline 0.9% to bring their systolic BP into perfusing range ( 90). So after all this mumbo jumbo, what exactly does this mean? The drug was effective in treating 99.8% of the patients. That is a significant number to keep in mind. With the recent repayment of their finance loan, reduction in workforce of 75% and continued involvement with Takeda’s management, I believe that AFFY is looking to be bought out. I personally despise the management team of AFFY but OMONTYS is valuable drug and with the right management and marketing can be a billion dollar blockbuster drug in the dialysis market. Obviously this is pure speculation on my part but with all the information available I consider it to be an educated guess. If you truly despise the company or are avert to high risk stocks, you should stay away from this company. However if you understand the fact, that a drug that cost a significant amount of capital to bring to the market and was voluntarily recalled by a company with incompetent management, then you should buy a few shares. Either way, good luck to all longs and obviously look at the quality of the subject matter of these internet posts rather than quantity to make your informed decisions on investments.
Very interesting point, obviously the bashers are the ones who rode it dn fro 27 to a buck, they are just #$%$ off, to buy for a buck is a cheap speculation, I love the risk reward, even minimize your risk with options, my gosh are they cheap.
Sentiment: Strong Buy
I do side with your thesis because Omontys is as safe as Epo and the major difference is the REMS and Amgen relative experience with handling Epo adverse events.Two cies that have compelling reason to buy Affy are either Amgen or Takeda. I did make the case for Amgen and layout the strategic reason for a buyout (Epo patent expiration, to keep their market share, Amgen valuable experience for dealing with ESA adverse events, ...etc),In addition both cies have a history of working together ( Takeda has in its pipeline three Amgen products in Phase 3). So far the setup (75% RIF, paying out the debt) is a hint of a likely buyout.